Abstract. Previous work from our group indicated a connection between the gastrointestinal 28 microbiota of infants and children with cystic fibrosis (CF) and airway disease in this population. 29 Here we examine the stool microbiota of infants with CF and from the general population who 30 did not have CF over the first year of life. CF children had reduced gastrointestinal Bacteroides 31
and Bifidobacterium beginning in infancy, even after adjusting for antibiotic treatment. We also 32
identify several metabolic pathways that are enriched or under represented among the 33 microbial communities in the stool of these young patients with CF as compared to children 34 without CF. In vitro studies demonstrated that exposure of the apical face of a polarized 35
Intestinal cell line to Bacteroides thetaiotaomicron significantly reduced production of IL-8 36 secreted from both the apical and basolateral face of these cells, suggesting a mechanism 37
whereby changes in the intestinal microflora could impact systemic inflammation. This work 38 further establishes a link between gastrointestinal microbiota, systemic inflammation and 39 airway disease, and presents the opportunity for therapeutic probiotic interventions. 40 41 Significance statement. There is a surprising link between gastrointestinal microbial 42 communities and airway disease progression in CF. Here we show that infants with CF <1 year 43 of age show a distinct stool microbiota compared with children of a comparable age from a 44 general population cohort. We detect associations between stool microbes and airway 45 exacerbation events in the cohort of infants with CF, and in vitro studies provide a possible 46 mechanism for this observation. These data argue that current therapeutics do not establish a 47
healthy-like gastrointestinal microbiota in young patients with CF, and we suggest that 48
interventions that direct the gastrointestinal microbiota closer to a healthy state may provide 49 benefit to these patients. 50
51
Text 52
Cystic fibrosis (CF) is an autosomal recessive disease that is known to significantly alter the 53 microenvironments in the airways, intestine and other organs, and is associated with systemic 54 complications such as chronic infections, pancreatic insufficiency, and ultimately premature 55 morbidity and mortality (1) (2) (3) (4) (5) (6) . While a great deal of attention has been focused on therapies to 56 treat the chronic airway infections that are often the proximal cause of mortality for these 57 patients, it is the gastrointestinal complications that are at the forefront for CF patients in early 58 life (7-10). Young patients with CF experience difficulty in absorbing nutrients secondary to 59 meconium ileus, pancreatic insufficiency and small bowel bacterial overgrowth (10-13). Poor 60 weight gain is common, resulting in the need for a high calorie diet starting early in life and 61 treatment with pancreatic enzyme replacement therapy (14). 62
Recent work has suggested an unexpected connection between the gastrointestinal tract and 63 airway function in young patients with CF. Our group has shown that select genera (e.g., 64
Enterococcus, Escherichia) colonizing the airway of CF patients tend to first appear in the 65 intestines (15). Furthermore, breastfed infants showed a longer period of pulmonary health 66
and stability prior to their first pulmonary exacerbation, with 20% of breastfed children having 67 no exacerbation over the first 30 months of life, compared to exclusively formula-fed infants, all 68 of whom suffered exacerbations by 9 months (16). Given the impact of breastfeeding on 69
intestinal microbiota composition (17-19), one possible explanation for these findings in CF is 70 an effect of intestinal microbial communities on airway disease outcomes. Consistent with this 71
idea, an analysis of a small group of patients (n = 13, ages 0-34 months) showed that 72 community composition in the intestine, rather than the airway microbiota, was significantly 73 associated with pulmonary exacerbations prior to age 6 months (16). 74
Here we further probe the relationship between the intestinal microbiota utilizing the 75
Dartmouth Cystic Fibrosis Infant and Children's Cohort compared with a subset of infants from 76 a general population cohort --the New Hampshire Birth Cohort Study. Using these two 77 cohorts, we characterize the differences between the intestinal microbiota of patients with CF 78 and the general population over the first year of life, both to understand the differences in the 79 microbiota associated with the intestinal tract in these two populations beginning in infancy, as 80 well as to determine if there is indeed a mechanistic link between intestinal microbiota and 81 airway disease outcomes through cell culture studies. 82
83
Results 84
Patient population. In this study, we analyzed 14 patients with CF and 20 non-CF infants at 4 85 months and 13 CF patients and 45 non-CF infants at 1 year. Of the subjects with CF, 8 had 86 paired samples analyzed at 4 months and 1 yr, and 6 samples were unique at the 2 time points. 87
The non-CF cohort were randomly selected from a larger cohort of children recruited through 88
the New Hampshire Birth Cohort Study for whom stool samples were collected at 89 approximately 4 months and one year of age (20-22). There was no overlap with the non-CF 90 subjects analyzed at 4 months and 1 year. DNA was extracted from stool samples and analyzed 91 for microbial communities as described in the Materials and Methods. 92
The alpha diversity of stool communities is altered in infants with CF in the first year of life. 93
To examine the impact of CF on community (alpha) diversity we calculated the Shannon 94
Diversity Index for infants with CF and without CF at 4 months and one year of age ( Figure 1 ). 95
Two key differences could be identified. First, at 4 months, the alpha diversity of the microbial 96 community in the stool of infants with CF was significantly higher than that of those subjects 97 without CF (p = <0.001). No observable change in diversity occurred between 4 months and 1 98
year in CF infants (p = 0.87); in contrast, the α-diversity did increase during this period in non-99 CF infants (p < 0.0001). Interestingly, the α-diversity of CF and non-CF children did not 100 significantly differ from each other at 1 year. These data indicate a significant difference in the 101 microbial diversity associated with the stool of infants with CF versus the comparison group of 102 non-CF children as early as 4 months of age. 103
The gut microbial communities of infants with CF differ from non-CF controls subjects over 104
the first year of life. We next analyzed the beta diversity (microbial community composition) of 105 the infants with CF in comparison to the non-CF comparison group. The beta diversity of 106 patients with CF and non-CF controls at 4 months is significantly difference ( Fig. 2A ; 107
PERMANOVA of generalized Unifrac distances; p = 0.002). Interestingly, despite the 108 observation that the alpha diversity of the subjects with CF and the comparison group is not 109 different at 1 yr, these stool samples show a significant difference in beta diversity ( Fig. 2B ; 110
PERMANOVA of generalized Unifrac distances; p = 0.001). Furthermore, the similar alpha 111 diversity of patients with CF at 4 months and non-CF children at 1 year is not reflected by a 112 similar microbial community, that is, the beta diversity of these samples is significantly different 113
( Fig S1; PERMANOVA of generalized Unifrac distances; p = 0.001). 114
Consistent with the significant difference in alpha diversity for non-CF children at 4 months and 115
1 year, there is a significant difference in beta diversity between these samples ( Fig. 2C ; 116
PERMANOVA of generalized Unifrac distances; p = 0.001). For children with CF, the similar 117 alpha diversity at 4 months and 1 year is also reflected by the clustering of communities, with 118 no significant difference in beta diversity ( Fig. 2D ; PERMANOVA of generalized Unifrac 119 distances; p = 0.396). 120
Alterations in the beta diversity of stool of infants with CF are driven by modest changes in 121
microbes for patients at 4 months of age. To further explore the basis of the differences in 122 beta diversity between subjects with CF and non-CF controls, we investigated differences in 123
individual OTUs, assigned at the genus level, when possible, or otherwise at the next lowest 124 taxonomic level. Selecting the top 25 OTUs in each data set resulted in a collection of microbes 125 that almost perfectly overlapped, and captured the top 20 OTUs for each cohort in terms of 126 relative abundance ( Fig. 3) . Using a Wilcoxon rank-sum test to compare the relative abundance 127 of genera present at 4 months, the abundance of Bifidobacterium is significantly higher in the 128 non-CF controls while Streptococcus, Veillonella, and Clostridium are significantly higher in 129 subjects with CF ( Fig. 3 ). Three lower abundance groups (~1% relative abundance for most 130 samples) are also significantly different: Faecalibacterium and two unassigned genera in the 131 order Clostridiales. None of the other nineteen most abundant OTUs are significantly different 132 at 4 months between these cohorts, thus only 6/25 microbes differ at the 4 month time point. 133
By one year of life, there are more significant differences between the cohorts, with 11/25 134 showing a significant difference in relative abundance between these cohorts ( Fig. S2 ). For 135 example, Bacteroides and Faecalibacterium are significantly higher in the non-CF comparison 136
group. There is no significant difference in Bifidobacteria levels between the cohorts at 1 year, 137 despite the significant difference at 4 months (Fig. 3) . Thus, particularly early in life (i.e., at 4 138 months), we find that the shift in microbes is primarily driven by a small subset of genera. 139
Microbes associated with immune programing are lower in patients with CF compared to 140 infants without CF. Given that subjects with CF demonstrate a lower abundance of Bacteroides 141 and/or Bifidobacterium at 4 months and/or 1 year than the comparison group, a more indepth 142 analysis of these two keystone immune programming genera was undertaken. While both 143
cohorts have individual subjects with low abundance of Bacteroides or Bifidobacterium, a 144 comparison of the relative abundance of each microbe at each sampling time revealed that for 145
the CF cohort at both 4 months and 1 year, there were a higher percentage of patients with 146 <1% relative abundance of these microbes and a lower maximal relative abundance compared 147
to the non-CF comparison cohort ( Figure S3 ). 148
Given the importance of Bacteroides and Bifidobacterium in immune programming (23, 24), it 149 was unexpected that even for the non-CF comparison cohort, some individuals had <1% of 150 these microbes. To investigate this observation further, the relative abundance of Bacteroides 151
versus Bifidobacterium on a subject-by-subject basis for both cohorts was plotted (Fig. S4) . For 152 the non-CF cohort, many subjects with low Bacteroides showed a high relative abundance of 153
Bifidobacterium, and visa versus (Fig. S4A ). There was also a group of non-CF patients with an 154 intermediate level of each microbe and ~50% of samples from the non-CF cohort had >40% 155 relative abundance of Bacteroides and/or Bifidobacterium. In contrast, for the CF cohort many 156 of the subjects clustered in a group with <20% of each microbe (Fig. S4B) , and there is only 1 157 subject with >40% of either Bacteroides or Bifidobacterium (~5% of the samples analyzed). 158
Subjects with CF and non-CF controls demonstrate differential enrichment of predicted 159 metabolic functions. Relative to the patients with CF, the non-CF comparison infant's microbial 160 community was associated with increased in functions connected with β-lactam resistance, 161 polyketide sugar unit biosynthesis, and carbohydrate metabolism (Fig. S5) . In contrast, subjects 162 with CF showed enrichment in processes that include restriction enzymes, streptomycin 163 biosynthesis, penicillin and cephalosporin biosynthesis, and galactose metabolism (Fig. S5 ). Our 164 analysis of the 4 month samples showed no significant enrichment of pathways for either 165 cohort, despite the significant differences in abundance of several OTUs (Fig. 3, S3 ). 166 enterotoxins that can stimulate the production of IL-8. Cho and colleagues showed that 170 exposing the apical face of intestinal epithelial cells to such a toxin resulted in the increased 171 production of IL-8 from the basolateral face of the same cell monolayer. These data indicate 172 that impacts to the host cells in the lumen of the intestine can have systemic impacts on 173 cytokine production. Thus, we assessed whether apical application of Bacteroides spp. can 174 reduce the basolateral production of IL-8. 175
Apical application of Bacteroides to intestinal epithelial cells reduces basolateral release of IL-
To investigate this mechanisms, we performed an experiment whereby Caco-2 cells were grown 176 on transwell filters as polarized monolayers, then inoculated on the apical face with ~3.5 x 10 7 177 CFU Bacteroides thetaiotaomicron (B. theta) . B. theta was not introduced into the basolateral 178 compartment. The IL-8 produced in the apical and basolateral compartments of the transwells 179
were measured after 24 hrs of exposure to the bacteria. We found apically inoculated B. theta 180 significantly reduced both the apical and basolateral production of IL-8 ( Fig. 4) We also thank Devin Harbin and Michelle Tyler for their assistance. Shannon diversity of samples from subjects with CF at 4 months of age as the reference group 351
in a generalized linear model, samples from CF subjects at 1 year of age are not significantly 352 different from the same cohort at 4 months (p = 0.87). Samples collected for the comparison
